FRANKLIN LAKES, N.J. (Aug. 1, 2024) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Patrick Jeukenne has been named worldwide president of the BD Pharmaceutical Systems business unit, effective today.

In this role, Jeukenne will be responsible for driving global strategic operational and commercial performance and customer experience across the Pharmaceutical Systems portfolio in line with the company’s BD 2025 strategy. He will be based out of Eysins, Switzerland, and report to Mike Garrison, executive vice president and president of the BD Medical Segment.

“Patrick brings more than 30 years of experience in driving innovation, growth and outcomes in global, cross-functional roles and is a seasoned and performance-focused leader,” said Garrison. “His robust track record spans the B2B pharmaceutical ecosystem, giving him a unique perspective and ability to continue advancing our innovation pipeline, and partner with customers to deliver the best outcomes and experiences for patients.”

Jeukenne rejoins BD from Aptar Pharma where he currently serves as vice president of Strategy, Business Development and Marketing along with leading drug and patient services. Jeukenne previously spent 13 years at BD where he made significant contributions through successive roles in sales management, commercial development for new injection technologies, innovation project management, integration of the SSI acquisition and led the Safety Devices platform as a member of the Pharmaceutical Systems leadership team. Jeukenne also formerly owned his own consulting practice as well as held roles at Federa (now part of Catalent), Amgen and GlaxoSmithKline (GSK).  

Jeukenne holds degrees from the Universities of Liège (Belgium) and Montpellier (France).

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:
Media:                                                                                                                  Investors:

Troy Kirkpatrick                                                                                                 Adam Reiffe
VP, Public Relations                                                                                         Sr. Director, Investor Relations
858.617.2361                                                                                                      201.847.6927        
troy.kirkpatrick@bd.com                                                                              adam.reiffe@bd.com